<DOC>
	<DOCNO>NCT00082329</DOCNO>
	<brief_summary>This 12-day study test whether combination G-CSF ( granulocyte-colony stimulating factor ) AMD3100 ( Mozobil ) efficient mobilize stem cell collection use G-CSF alone . Traditionally , growth factor G-CSF give stem cell donor mobilize , push , stem cell bone marrow blood circulation collection transplantation . Although sufficient quantity cell usually collect G-CSF treatment , donor respond well may require multiple apheresis procedure ( see ) collect enough cell . Studies indicate G-CSF use together drug call AMD3100 may effective mobilize stem cell collection G-CSF alone . The Food Drug Administration approve G-CSF stem cell mobilization . AMD3100 new drug also mobilize stem cell large number within hour . Normal healthy volunteer 18 60 year age may eligible study .</brief_summary>
	<brief_title>G-CSF AMD3100 Mobilize Stem Cells Healthy Volunteers</brief_title>
	<detailed_description>Peripheral blood progenitor cell ( PBPC ) popular source hematopoetic stem cell allogeneic transplantation technical ease collection faster engraftment . Traditionally , granulocyte-colony stimulating factor ( G-CSF ) use procure peripheral blood stem cell graft . Although regimen use G-CSF usually succeed collect adequate number PBPC healthy donor , 5 % -10 % donor mobilize stem cell poorly may require multiple large volume apheresis bone marrow harvest . AMD3100 reversibly inhibit CXC- chemokine receptor 4 ( CXCR4 ) bind stromal cell derive factor ( SDF ) - 1 recently discover effective agent mobilize cluster differentiation 34 ( CD34 ) + cell peripheral blood . In normal volunteer , administer AMD3100 4-5 day G-CSF result 3-3.5 fold increase circulate CD34 cell compare G-CSF alone . Recent data suggest combination G-CSF AMD3100 superior G-CSF alone mobilize hematopoietic progenitor cell heavily pretreated patient multiple myeloma non-Hodgkin 's lymphoma undergo autologous hematopoietic transplantation . Combining AMD3100 G-CSF could effective strategy improve yield PBPC collect allogeneic donor mobilize poorly G-CSF alone . However , biological impact AMD3100 context T cell cellular population contain within allograft mediate graft versus host disease ( GVHD ) graft-versus-leukemia ( GVL ) effect unknown . We propose collect peripheral progenitor cell ( PBPC ) healthy volunteer follow 5 day G-CSF ( 10 mcg/kg/day ) single dose AMD3100 ( 240 mcg/kg subcutaneous give 12 hour start apheresis ) study impact combine two mobilize agent immunological property mobilize cell . A single 15 liter apheresis conduct day 5 follow 5th dose G-CSF . The immunological study conduct mobilized cell parallel study investigate immune property PBPCs mobilize G-CSF AMD3100 alone . If combine AMD3100 G-CSF negative impact immune population involve GVHD graft-vs-leukemia effect , regimen could use allogeneic donor fail mobilize sufficient peripheral blood stem cell ( PBSC ) use G-CSF alone . Primary objective : To determine cytokine polarization status cluster differentiation 4 ( CD4+ ) T-cells collect apheresis follow combination AMD3100 G-CSF compare G-CSF mobilization . Primary endpoint : ratio Th1 [ intracellular interferon ( IFN-g ) + ] versus Th2 [ intracellular interleukin ( IL-4+ ) ] T-cells apheresis product collect individual donor undergo mobilization combination G-CSF AMD3100 ratio apheresis product collect G-CSF alone ( ratio publish literature ) . Secondary endpoint : To examine 1 ) cellular content immune property mobilize cell ; 2 ) yield hematopoietic progenitor cell , immune cell , cellular subset collect apheresis ; 3 ) safety profile AMD3100 .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>INCLUSION CRITERIA : Healthy volunteer great equal 18 year old , less equal 60 year . Weight great 60 kg ( 132 pound ) Normal renal function : creatinine le 1.5 mg/dl l Normal liver function : bilirubin less than1.5mg/dl , transaminase within normal limit Normal blood count : white blood cell ( WBC ) 300010000/mm3 , granulocyte great 1500/mm3 , platelet great 150,000/mm3 , hemoglobin great 12.5g/dl Subject must eligible normal blood donation fit undergo apheresis procedure ( antecubital vein must adequate peripheral access apheresis ) Ability comprehend investigational nature study provide inform consent EXCLUSION CRITERIA : follow Active infection history recurrent infection positive test syphilis ( RPR ) , hepatitis B C ( HBaSAg , AntiHCV ) , HIV human T Lymphocytic virus ( HTLV1 ) History autoimmune disease rheumatoid arthritis , systemic lupus erythematous History cancer within past 5 year exclude basal cell squamous cell carcinoma skin History hematologic disorder include thromboembolic disease History cardiac disease uncontrolled hypertension , peripheral vascular disease , myocardial infarction , cardiac arrhythmia relate symptom tachycardia , chest pain , shortness breath require medical intervention treatment Framingham coronary disease risk prediction score great 10 % 10 year coronary heart disease ( CHD ) risk History heavy smoking underlying pulmonary disease History cerebrovascular disease , transient ischemic attack , stroke Diagnosis sickle cell anemia sickle cell trait ( screen hemoglobin ( Hbg ) electrophoresis ) Pregnant lactate Severe psychiatric illness : mental deficiency sufficiently severe make informed consent impossible . Mobilization GCSF within 90 day protocol enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Hematopoietic Stem Cells</keyword>
	<keyword>PBSC 's</keyword>
	<keyword>Mobilization</keyword>
	<keyword>Alloreactivity</keyword>
	<keyword>T Cell Polarization</keyword>
	<keyword>Dendritic Cells</keyword>
	<keyword>CXCR4</keyword>
	<keyword>Plerixafor</keyword>
	<keyword>Healthy Volunteer ( HV )</keyword>
</DOC>